Insights into cell ontogeny, age, and acute myeloid leukemia

Shahzya Chaudhury, Jessica Kate Morison, Brenda Gibson, Karen Keeshan

Research output: Contribution to journalLetterOther

21 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is a heterogenous disease of hematopoietic stem cells (HSCs) and progenitor cells (HSPCs). The pathogenesis of AML involves cytogenetic abnormalities, genetic mutations, and epigenetic anomalies. Although it is widely accepted that the cellular biology, gene expression, and epigenetic landscape of normal HSCs change with age, little is known about the interplay between the age at which the cell becomes leukemic and the resultant leukemia. Despite its rarity, childhood AML is a leading cause of childhood cancer mortality. Treatment is in general extrapolated from adult AML on the assumption that adult AML and pediatric AML are similar biological entities. However, distinct biological processes and epigenetic modifications in pediatric and adult AML may mean that response to novel therapies in children may differ from that in adults with AML. A better understanding of the key pathways involved in transformation and how these differ between childhood and adult AML is an important step in identifying effective treatment. This review highlights both the commonalities and differences between pediatric and adult AML disease biology with respect to age.
Original languageEnglish
Pages (from-to)745 - 755
Number of pages11
JournalExperimental Hematology
Volume43
Issue number9
DOIs
Publication statusPublished - 2015
Externally publishedYes

Cite this